Real-World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results from a Canadian Cohort.
Under-valuing the effectiveness of conventional treatments may lead to overtreatment with biologic medications in children with juvenile idiopathic arthritis (JIA). We used data from a nation-wide inception cohort and strict methods to control bias to estimate the real-world effectiveness of simple JIA treatment strategies recommended in current guidelines. Children with JIA recruited at 16 Canadian centers in 2005-2010 were followed for up to 5 years. For each child, all observed treatment changes over time were assessed by independent physicians using prospectively collected data and published response criteria. Success was defined as attainment of inactive disease or maintenance of this state when stepping down treatment; minimally active disease was acceptable for children with polyarticular course. Success rates were calculated for treatments tried ≥25 times and logistic regression identified features associated with success. 4,429 treatment episodes were observed in 1352 children. NSAID monotherapy was tried 697 times, mostly as initial treatment when <5 joints were involved, with 54.4% success (CI: 50.3-58.6). NSAID plus joint injections had 64.7% success (CI: 59.8-69.7). Adding methotrexate to NSAID and/or joint injections, tried 566 times, had 60.5% success (CI: 55.7-65.3). In adjusted analyses, each additional active joint reduced chances of success for NSAID (OR=0.90, CI: 0.85-0.94) and for methotrexate combinations (OR=0.96, CI: 0.94-0.99). Each additional year after disease onset reduced chances of success with methotrexate combinations (OR=0.83, CI: 0.72-0.95). These real-world effectiveness estimates show conventional non-biologic treatment strategies recommended in current guidelines are effective in achieving treatment targets in many children with JIA. This article is protected by copyright. All rights reserved.